G-protein coupled receptors signaling bitter taste (T2Rs) in the oral gustatory system and the subunit of the taste-specific G-protein gustducin (G gust) are expressed in the gastrointestinal (GI) tract. G gust co-localizes with markers of enteroendocrine cells in human and mouse gastrointestinal mucosa, including peptide YY (PYY).
Introduction
T2Rs are a family of G-protein-coupled receptors that are expressed on the tongue and palate epithelium in humans and rodents, and are involved in sensing bitter taste (12, 37) . The human T2R family is composed of 33 members (38) and both mouse and rat T2R families consist of 36 intact genes (56) . T2Rs and the subunit of the taste-specific G-protein gustducin (G gust) are also found in rodent gastrointestinal (GI) tract (25, 50, 55) . G gust is expressed in brush cells of the rat stomach and duodenum (25) and mouse small intestine (50) . Co-localization of G gust with peptide YY (PYY) and glucagonlike peptide-1 (GLP)-1 in enteroendocrine L cells of human colonic mucosa has been reported (47) . In addition, G gust is co-localized with GLP-1 and 5-hydroxytryptamine in the mouse small intestine (50) . T2R mRNA has been identified in the mucosa of stomach and duodenum (55, 56) and in the human colon (47) . The presence of transcripts corresponding to the putative denatonium benzoate (DB) and phenylthiocarbamide (PTC) receptors, mT2R108 in mouse (rT2R16 in rat) and mT2R138 (rT2R38), respectively, have been demonstrated in mouse and rat upper GI tract, and in a mouse GI enteroendocrine cell line, STC-1 (56) . Application of ligands for the T2Rs including DB and PTC to STC-1 cells induces rapid Ca 2+ signaling (14, 56) , indicating that T2Rs in these cells are functional. Release of cholecystokinin (CCK) is induced by application of DB to STC-1 cells (14) . Thus, there is evidence to demonstrate the existence of T2Rs in the GI tract and enteroendocrine cell lines, but little is known of their function.
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It is well established that regulatory peptides released from GI endocrine cells in response to luminal stimulation by nutrients result in changes in GI function, including inhibition of gastric emptying, and gastric acid secretion, pancreatic enzyme secretion, intestinal motility and inhibition of food intake (46) . A major pathway by which regulatory peptides induce change in function is via activation of extrinsic neural pathways, predominantly the vagal afferent pathway (21) . Vagal afferents play an important role in gut-brain communication, responding to both mechanical and chemical stimuli. Activation of vagal afferents causes excitation of neurons in the nucleus of the solitary tract (NTS), followed by reflex activation of vagal efferent neurons which results in changes in GI function (22) . In addition, information carried in vagal afferents from the GI tract to the central nervous system is involved in the regulation of food intake and feeding behaviors (48) and in nausea and vomiting (5) .
CCK is a well-established gut-brain regulatory peptide. It is released from endocrine cells in the upper small intestine in response to the presence of nutrients (17), and it exerts its effect via two receptor subtypes, CCK 1 and CCK 2 . CCK 1 receptors are abundant in peripheral organs (24, 35, 36, 49) , while the CCK 2 receptors are the predominant form found in the CNS (19, 35) . CCK acts on CCK 1 receptors on vagal afferent nerve terminals in the intestinal mucosa (9, 45) , subsequently resulting in stimulation of neurons in the NTS (13, 15) and activation of vagal reflexes (44) .
PYY is a 36 amino acid, straight chain polypeptide, released from the L-type endocrine cells of the GI mucosa. After release, dipeptidyl peptidase IV cleaves the N-
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terminal tyrosine-proline residues forming PYY (34) . PYY represents about 60% and PYY 40% of circulating PYY (20) . PYY acts through Y-receptor subtypes: Y 1 , Y 2 , Y 4 and Y 5 . PYY shows high affinity to all four receptors while PYY 3-36 is a specific Y 2 agonist (26). Both PYY 1-36 and PYY cross the blood-brain barrier and participate in appetite and weight control regulation. It has been suggested that PYY acting through Y 2 receptors in the arcuate nucleus decreases appetite and promotes weight loss (1, 8) . However, Y 2 receptors are also expressed by neurons in the nodose ganglion and transported to the vagal afferent nerve terminals (28) . The anorectic effect of peripheral administration of PYY 3-36 on food intake was abolished following either bilateral sub-diaphragmatic total truncal vagotomy or brainstem-hypothalamic pathway transection in rodents (2, 28) . These findings indicate that peripheral PYY 3-36 may transmit signal to the brain via activating Y 2 receptors on the vagal afferents.
In the present study, we tested the hypothesis that stimulation of T2Rs expressed by the GI mucosa activates the vagal afferent pathway by a mechanism involving CCK 1 and Y 2 receptors. The specific aims were to determine 1) whether activation of T2Rs in the GI tract stimulate neurons in the medial NTS, the region in the brainstem where vagal afferents from GI tract terminate, and whether this occurs through a vagal pathway, using fos protein as a marker of neuronal activation and subdiaphragmatic vagotomy and 2) whether activation of NTS neurons involves the CCK 1 and Y 2 receptors. 
EXPERIMENTAL PROCEDURES Animals
Experiments were performed using eight-week male C57/B6 mice (JaxWest, University of California, Davis, CA, USA), CCK 1 receptor knockout mice (CCK 1 R -/-) (29, 52) and their wild type counterparts (CCK 1 R +/+ ; 129S6/SvEv, Taconic, Oxnard, CA).
Mice were maintained on regular laboratory chow and fasted overnight on wire-bottom cages but allowed water ad libitum prior to all experimental procedures. The UC Davis institutional guidelines for care and use of laboratory animals were followed throughout the study.
Reagents
The CCK 1 receptor antagonist, devazepide (kindly donated by Merck, Sharpe and Dohme) was dissolved in 0. 
Subdiaphragmatic Vagotomy
Subdiaphragmatic vagotomy was performed as previously described (23) . Mice were fasted overnight before surgery. Under anesthesia (Avertin 250mg/kg, i.p.) and aseptic conditions, a midline laparotomy incision was made to expose the peritoneal cavity. The distal 1 cm of the esophagus were stripped of the external muscle coat; as the vagal branches are associated with the muscle coat, this results in a subdiaphragmatic vagotomy. In addition, to ensure the completeness of vagotomy, the left gastric artery was isolated and stripped of all connective tissues and nerves, which includes the accessory branch of the vagus. Another group of mice underwent a sham operation (opening of the abdomen and manipulation of the stomach and esophagus). Animals were housed individually after the surgery and maintained on a liquid diet (Ensure) and water ad libitum. Mice were allowed to recover for 7-10 days before experimental use.
Pharmacological Treatments
Before the treatment day, mice were acclimated to three days handling which included weighing and massaging the stomach to stimulate the future injection site.
Fasted mice were intragastrically gavaged with either 100µl ddH 2 O (control), DB (10 mM), PTC (10 mM) or 100µl of a bitter taste receptor agonist mixture (DB 10 mM, PTC 10 mM, 6-propyl-2-thiouracil 5 mM, quinine 5 mM and D-[-]salicin 5 mM). Intragastric gavage was used so that the bitter taste receptor agonists would be administered directly to the lumen of the GI tract and thus bypassing the oral cavity. Care was taken to ensure that there was no fluid on the tip or the outside of the gavage needle.
In some experiments, the CCK 1 receptor antagonist, devazepide (100µg/kg IP) (54) or Y 2 receptor antagonist, BIIE0246 (50µg/mouse IP) (51) was administered 15 min prior to intragastric gavage.
Immunohistochemistry: c-fos protein expression in the NTS
As described previously (53) , two hours following treatment, mice were Images were taken on a Provis microscope and analyzed using paint Shop Pro, Edition 7. A stereotaxic mouse brain atlas was used to determine the location of the NTS in each section of tissue (39) . A region of interest was drawn around the NTS and all activated neurons in the NTS region of interest were counted.
Neurons were considered immunopositive (above threshold) by their staining and size. Representative sections were chosen corresponding to different regions of the NTS: caudal NTS (bregma -8.24 to -7.92 mm), mid-NTS (-7.76 to -7.32 mm) and rostral NTS (-7.08 to -6.48 mm). Three sections were chosen for each region for a total of nine sections per mouse. The numbers of labeled neurons per section were summed for each region for each mouse; this value was used in subsequent statistical analyses (53) .
Statistical analysis
Significant differences in the number of Fos positive neurons between treatment groups were analyzed by two-way ANOVA followed by Holm-Sidak multiple comparison test (SigmaStat). Significant level was defined as P<0.05. Results are presented as the number of fos-positive neurons ± standard error of the mean.
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RESULTS
Effect of intragastric administration of a mixture of bitter taste receptor agonists
Initial experiments were performed with a mixture of bitter taste receptor agonists in order to activate multiple T2Rs. Intragastric administration of the bitter taste receptor agonist mixture significantly increased the number of fos-positive neurons in the mid-NTS in both normal and sham-operated mice compared to control mice that received gavage of vehicle (water) (Fig 1; p<0.05; n=5-7) . This increase in the number of fospositive neurons in response to intragastric gavage of bitter taste receptor agonists was completely abolished in mice in which the subdiaphragmatic vagus nerves had been sectioned (Fig 1; p<0.05, n=5 ). In mice following sham operation or in which the subdiaphragmatic vagus nerve was sectioned and were gavaged with water, the numbers of fos-positive neurons were not significantly different from control mice (data not shown).
The increase in fos-positive NTS neurons was observed at the level of mid-NTS (bregma -7.32 to -7.76). There was no significant increase in the number of fos-positive neurons in the NTS at levels caudal or rostral to this area following intragastric gavage of bitter taste receptor agonist mixture (Fig 2) . Therefore, only the number of fos-positive neurons in the mid-NTS is presented in the subsequent text and figures.
Role of CCK 1 and Y 2 receptors in mediating activation of the NTS in response to DB
Intragastric administration of DB (10mM) significantly increased the number of fos-positive neurons in NTS compared to intragastric administration of vehicle in both Page 10 of 26 11 C57/B6 and CCK 1 R +/+ mice (Fig 3, n=5-6 in each group, p<0.05). This increase in fospositive neurons in NTS in response to intragastric administration of DB was significantly reduced in CCK 1 R -/compared to CCK 1 R +/+ mice (Fig 3a; p<0 .05, n=5-6 in each group). In addition, the increase in the number of fos-positive neurons in the NTS following intragastric administration of DB was completely abolished in mice pre-treated with either the CCK 1 R antagonist devazepide or the Y 2 receptor antagonist BIIE0246 (Figure 3b, p<0 .05, n=3-5).
Role of CCK 1 and Y 2 receptors in mediating activation of the NTS in response to
PTC
Intragastric administration of PTC (10 mM) to C57/B6 or CCK 1 R +/+ mice significantly increased the number of fos-positive neurons in the NTS (Fig. 3a and b; n=4-5, p<0.05). However, there was no significant difference in the number of fospositive neurons in response to PTC in the CCK 1 R +/+ compared to CCK 1 R -/mice (n=4-5, p>0.05). Blockade of Y 2 receptors in C57/B6 mice had no effect on the activation of the NTS in response to PTC (Fig. 3b, n=4 in each group, p>0.05).
DISCUSSION
The present study shows that activation of multiple T2Rs, presumably expressed by endocrine cells in the mucosa of the GI tract, induces c-fos expression in neurons in the mid-region of the NTS, where the majority of afferent fibers from the proximal GI tract terminate (3, 4) , with little activation of rostral and caudal regions. The increase in the number of fos-positive NTS neurons was prevented by subdiaphragmatic vagotomy, suggesting that the response of NTS neurons was induced by an action of bitter taste receptor agonists at the level of the subdiaphragmatic viscera. However, we cannot discern the exact site of action which could be in the stomach or the proximal small intestine, or both. Taken together, these data suggest that bitter taste receptor agonists in the gut lumen act on receptors localized to endocrine cells in the mucosa of the GI tract, resulting in activation of the vagal afferent pathway. CCK 1 and Y 2 receptors are expressed by nodose neurons and localized to vagal afferent nerve terminals in the GI mucosa (9, 28) . We investigated whether the response of NTS neurons to intraluminal administration of bitter taste receptor agonists involved either CCK 1 Rs or Y 2 receptors. Intragastric administration of DB alone, a putative selective ligand for mT2R108, elicited a significant activation of NTS neurons that was not observed in mice lacking CCK 1 Rs (CCK 1 R -/-) and was prevented by pretreatment a Y 2 receptor selective antagonist. In contrast, lack of CCK 1 receptors and inactivation of Y 2 receptors did not affect the ability of NTS neurons to respond to PTC, a preferred ligand for the mT2R138. These findings suggest a selectivity of the neuronal response in the NTS to agonists acting at different T2Rs. The involvement of CCK 1 and Y 2 receptors in the activation of vagal afferents in response to DB implies that activation of DBpreferred T2R evokes CCK and PYY release. This is consistent with the observation that DB potently stimulates CCK release from an intestinal endocrine cell line of STC-1 cells (14) , and is supported by the expression of G gust, a G-protein subunit that mediates gustatory signals in the tongue, in enteroendocrine L cells that express PYY in the human colonic mucosa (47) . Furthermore, our findings for selectivity of different bitter taste Page 12 of 26 13 receptors with DB and PTC are consistent with receptor selectivity for bitter tastants in the human tongue. Indeed, in humans, detection of the bitter compounds such as salicin, PTC and DB is thought to be mediated by three different receptors of the T2R family, hT2R16 (11) , hT2R38 (27) and hT2R44 (40) , respectively. The latter two receptors are the homologues to mouse T2R138 (PTC receptor) and mT2R108 (DB receptor), respectively (56) .
It is interesting to note that either CCK 1 R or Y2 receptor blockade abolished the response to DB. This data is not readily explained in terms of our current understanding of the vagal afferent pathway. However, the majority of vagal afferent neurons expressing the Y2 receptor also express the CCK 1 R (Dockray, personal communication) so an interaction at the level of the vagal afferent pathway is possible. In addition, CCK regulates PYY release via CCK 1 receptors (16, 32) and this could account for the observation. Alternatively, it has been shown that CCK and PYY have direct effects on NTS neurons (6, 10) . Thus, it is possible that the action of CCK is at the level of the vagus nerve and the action of the Y2 receptor is at the level of the NTS via the Y2 receptor.
Taken together, the present findings suggest an involvement of vagal afferents, including those expressing CCK 1 and Y 2 receptors in mediating the activation of neurons in the NTS by T2R agonists. Activation of the vagal afferent pathway is important for the regulation of GI function when food is in the intestinal lumen. Perfusion of the intestine with nutrients activates neurons in the NTS and this is mediated by CCK 1 receptors likely located on the peripheral terminals of vagal afferents that terminate close to the base of CCK-secreting enteroendocrine cells. CCK and PYY have shown to exert a number of biological actions on GI functions including effects on gastric motility (42), gastric emptying (41, 43, 52) , gastric acid secretion (33, 52) , pancreatic secretion (30), gallbladder contraction (31) and control of food intake (7, 13, 15) . It is likely that activation of the vagal afferent pathway by bitter taste receptor ligands and subsequent release of regulatory peptides such as CCK and PYY will produce changes in GI function; however, this remains to be investigated. It should be noted that the current experiments do not provide definitive evidence that these ligands are acting at the T2R receptor; it is consistent with the known localization to CCK and PYY endocrine cells in the gut wall.
Perspectives and Significance
This study demonstrates that bitter taste agonists acting at multiple T2Rs as well as individual agonists like DB and PTC that preferentially bind mT2R108 and mT2R128, 
